Cytopoint
lokivetmab
Table of contents
Overview
Cytopoint is a veterinary medicine used to treat atopic and allergic dermatitis in dogs. Dermatitis is inflammation of the skin that is linked to allergy, often to things in the environment such as house dust mites and pollens. Once the dog’s skin becomes damaged by scratching and rubbing, secondary bacterial and yeast infections may develop as well.
Cytopoint contains the active substance lokivetmab.
Authorisation details
Product details | |
---|---|
Name |
Cytopoint
|
Agency product number |
EMEA/V/C/003939
|
Active substance |
lokivetmab
|
International non-proprietary name (INN) or common name |
lokivetmab
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QD11AH91
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
6
|
Date of issue of marketing authorisation valid throughout the European Union |
25/04/2017
|
Contact address |
Rue Laid Burniat 1 |
Product information
09/09/2020 Cytopoint - EMEA/V/C/003939 - II/0009
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Other dermatological preparations
-
Agents for dermatitis, excluding corticosteroids
Therapeutic indication
Treatment of clinical manifestations of atopic dermatitis in dogs.